AbClon Inc - Asset Resilience Ratio

Latest as of March 2025: 14.74%

AbClon Inc (174900) has an Asset Resilience Ratio of 14.74% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 174900 total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

₩4.86 Billion
≈ $3.29 Million USD Cash + Short-term Investments

Total Assets

₩32.96 Billion
≈ $22.34 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how AbClon Inc's Asset Resilience Ratio has changed over time. See AbClon Inc net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down AbClon Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 174900 market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩1.86 Billion 5.64%
Short-term Investments ₩3.00 Billion 9.1%
Total Liquid Assets ₩4.86 Billion 14.74%

Asset Resilience Insights

  • Moderate Liquidity: AbClon Inc has 14.74% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

AbClon Inc Industry Peers by Asset Resilience Ratio

Compare AbClon Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Fortress Biotech Inc
NASDAQ:FBIO
Biotechnology 11.59%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 0.00%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Apellis Pharmaceuticals Inc
NASDAQ:APLS
Biotechnology 0.58%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
BrightGene Bio Medical Technology C
SHG:688166
Biotechnology 1.00%
BioArctic AB (publ)
ST:BIOA-B
Biotechnology 72.35%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%

Annual Asset Resilience Ratio for AbClon Inc (2015–2024)

The table below shows the annual Asset Resilience Ratio data for AbClon Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 45.37% ₩21.86 Billion
≈ $14.82 Million
₩48.18 Billion
≈ $32.65 Million
+6.85pp
2023-12-31 38.53% ₩17.50 Billion
≈ $11.86 Million
₩45.42 Billion
≈ $30.78 Million
-6.13pp
2022-12-31 44.65% ₩24.14 Billion
≈ $16.36 Million
₩54.06 Billion
≈ $36.64 Million
+10.24pp
2021-12-31 34.42% ₩10.27 Billion
≈ $6.96 Million
₩29.83 Billion
≈ $20.21 Million
-14.30pp
2020-12-31 48.72% ₩19.55 Billion
≈ $13.25 Million
₩40.13 Billion
≈ $27.20 Million
-11.83pp
2019-12-31 60.55% ₩28.44 Billion
≈ $19.27 Million
₩46.97 Billion
≈ $31.83 Million
-11.02pp
2018-12-31 71.57% ₩20.54 Billion
≈ $13.92 Million
₩28.70 Billion
≈ $19.45 Million
-10.40pp
2017-12-31 81.97% ₩17.10 Billion
≈ $11.59 Million
₩20.87 Billion
≈ $14.14 Million
+9.25pp
2016-12-31 72.72% ₩11.64 Billion
≈ $7.89 Million
₩16.01 Billion
≈ $10.85 Million
+10.87pp
2015-12-31 61.85% ₩10.00 Billion
≈ $6.78 Million
₩16.17 Billion
≈ $10.96 Million
--
pp = percentage points

About AbClon Inc

KQ:174900 Korea Biotechnology
Market Cap
$635.95 Million
₩938.42 Billion KRW
Market Cap Rank
#11309 Global
#346 in Korea
Share Price
₩49150.00
Change (1 day)
-2.48%
52-Week Range
₩9630.00 - ₩89100.00
All Time High
₩90600.00
About

AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company's products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is… Read more